What an absolute honor to chair the papillary RCC Education Session at #ASCO26! 🙌🔬
Papillary renal cell carcinoma is a disease that demands our attention, and this session covered the full spectrum 🧬 — biology ➡️ frontline ➡️ refractory disease.
I was thrilled to review subsequent lines + novel therapeutic approaches for refractory papillary RCC 💉💙, including the emerging strategies and clinical trial opportunities that give me so much hope for our patients. 🌟
Huge thanks to my incredible co-faculty Dr. Ramaprasad Srinivasan 🧠 & @charlesbnguyen for such an engaging discussion — collaboration like this is what moves the field forward! 🚀
#KidneyCancer #RCC #GUOncology @ASCO@urotoday@JCO_ASCO@ASCOPost@charlesbnguyen@OncoAlert@UCSF
Congrats to Dr Armstrong and colleagues for CHAMP study showing quadruplet chemo immunotherapy results in much better outcomes for patients with AVPC and teNEPC - need more trials for these most aggressive #prostatecancer#ASCO26
Unsung hero poster award for RCC. @OncHahn discusses muscle and fat changes in patient receiving either Len/Ev or Cabo with some interesting findings that complement standard toxicity data.
Great combo of presys by Dr. Mateo and @neerajaiims show ADT + enza + tala improves rPFS for APMS prostate cancer and how ADT + enza induces transcriptome changes but not HRD
Cheers to @neerajaiims on his presentation of the #TALAPRO3 data w simultaneous @NEJM publication! It reflects the dream of many clinical investigators in #oncology - to lead a trial & generate paradigm shifting data in a field that you have devoted your life to (in this case, #prostatecancer).
If you see him at #ASCO26, inquire about his remarkable story. At @huntsmancancer, he built the GU program from scratch into one of the highest performing programs worldwide. He did this over the span of nearly two decades through mentorship of his faculty & fellows (@umangtalking@maughanonc@ziremozay@ggebraelmd et al), extensive outreach to the local community & active participation & leadership in multiple studies (a mix of industry, ISTs & @SWOG). Simply amazing.
When a doctor becomes a patient, we witness a different kind of illness narrative: one that opens up the 'clinical encounter' in a whole different way. Lucky for us as patients and lucky for clinicians too, @RanaAwdish opens our eyes + minds once again when her new book "After Shock" comes out in June.
Honored to have her essay in our new anthology too!
(1/3) Here is our clinical lab’s latest work on how body composition influences the efficacy of nivo + ipi for pts with metastatic ccRCC https://t.co/V1wx3eXzrg in @jitcancer Led by @kgre23@MourattJulia and collab with @PavlosMsaouel lab
UNITE study analysis @ASCO#GU26 evaluating prior IO exposure and outcomes with EVP in aUC:
68 had prior IO
⬇️PFS: 6.7 vs 11.7 months (HR 1.60)
⬇️ OS: 13.3 vs 21.9 months (HR 1.53) IO–EVP interval not associated with improved outcomes
Important considerations for sequencing
At #GU26 a tremendous overview of optimal trial design by @PavlosMsaouel. Pavlos has repeatedly shown that even in very rare cancers, optimally designed studies can rapidly led to practice changing findings. A visionary in our field.
⭐ Take a look at our deep dive on @UCSFCancer's multidisciplinary approach to #bladdercancer care: https://t.co/bwS6PBlwG9
📺 We spoke with multiple experts across the spectrum of care, including @xiaolin_zhu, @CChuMD, @thomashopemd, and more.
I am deeply grateful to share that I matched at @MDAndersonNews 🙌🌟
This journey has been made even more meaningful by the incredible #mentors who guided me and the amazing #faculty I interacted with during my fellowship interviews.
Thanks to all programs for the opportunity!